ArticleCancer biomarkers : section A of Disease markers2018

Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer.

Ge Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.